secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-10-18T23:59:59+00:00
Accession:  0001193125-24-239687
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors
--------------------------------------------------------------------------------

- Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.
- Errors: weighted average ordinary shares outstanding incorrectly used ending shares instead of weighted average.
- Restatement affects only IFRS-based financials in 2022 Annual Report; 2023 US GAAP financials not impacted.
- Company intends to file amendment to 2022 Annual Report as soon as practicable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524239687/0001193125-24-239687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524239687/d894508d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-239687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer